UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorUbix Therapeutics, Inc.
About this trial
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of UBX-303061 in patients with relapsed/refractory B-cell malignancies.
Eligibility criteria
Qualifiers
Capable of giving signed informed consent
Age ≥18 years
ECOG performance status ≤2.
Phase Ia (dose-escalation part only): Subjects with relapsed and/or refractory B-cell malignancies (CLL/SLL, DLBCL, FL, MCL, WM or MZL) who have received at least 2 prior therapies and for subjects with no available treatment options as per the Investigator's discretion.
Disqualifiers
Systemic antineoplastic therapy or any experimental therapy within 3 weeks or 5 half-lives, whichever is shorter, before the first dose of study treatment.
Therapy with tyrosine kinase inhibitor within 5 half-lives before the first dose of study treatment.
Unconjugated monoclonal antibody therapies <6 weeks before the first dose of study treatment.
Subjects that have undergone autologous stem cell rescue within 100 days prior to the first dose of study treatment.
Trial design
Treatments tested in this trial
- UBX-303061
Treatment groups
94 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov